Given the role of AP-1 in the regulation of key inflammatory mediators known to promote RA, targeting it is a potential treatment solution; however, there are no FDA-approved AP-1 inhibitors available in the clinic. This evidence concerns the gene JUN and rheumatoid arthritis.